BioCentury
ARTICLE | Clinical News

HT-100: Phase Ib/IIa started

July 29, 2013 7:00 AM UTC

Dart's Halo Therapeutics LLC subsidiary began an open-label, U.S. Phase Ib/IIa evaluating single and multiple ascending-doses of HT-100 in about 30 males aged 6 to 20 years with DMD. The Phase IIa po...